FIT-039 suppressed both HPV E6 and E6*I (E6-spliced form)/E7 transcripts in a dose-dependent manner, and p53 and pRb tumor suppressors targeted by HPV E6 and E7 were restored after FIT-039 treatment.93 Additionally, FIT-039 treatment showed growth-suppressive effects comparable to those of E6 and E7 knockdown in CaSki cells (HPV+ cervical cancer cells).93 A significant retardation of HPV16+ CaSki xenograft tumor growth was observed in mice treated with 300 mg/kg BW FIT-039.93 The gene discussed is TP53; the disease is neoplasm.